A Parkinson disease review described clonazepam as an established option for REM sleep behavior disorder, but its discussion of a placebo-controlled trial was more cautious than its broad conclusions.
Yan and colleagues reviewed pharmacological treatments for REM sleep behavior disorder in Parkinson disease. This disorder involves dream-associated movements and can cause injury to patients and bed partners. The review included seven studies, with different treatments and methods of measuring improvement.
For clonazepam, the authors discussed a four-week randomized, double-blind trial involving 40 participants. A clinical impression score did not show a statistically significant difference between clonazepam and placebo; the reported p value was 0.253. Both groups tended to improve.
The review noted that the trial relied on a clinical impression measure without further clarification through polysomnography. A clinical rating, an overnight recording, and a report of injury frequency answer related but different questions. A favorable general description of treatment cannot replace the specific result of the controlled comparison.
The authors also discussed morning sedation, confusion, dizziness, and falls as concerns, particularly in older people and those with neurodegenerative disease. These are relevant when balancing symptom control against unwanted effects.
This is a review of a small and varied literature, rather than a new demonstration of clonazepam efficacy. A nonsignificant result does not establish that treatment never works, but it also does not establish superiority over placebo. In an expert report, identify the actual trial, follow-up period, and endpoint before adopting the review’s broader therapeutic language. The paper does not establish a blood concentration threshold for injury or impairment.
Based on the supplied paper: Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson s Disease A Systematic Re. PMC8415017.